About Us
History
HomeAbout UsHistory
ABL Bio History
History of ABL Bio
2025
-
04
Signs licensing agreement with GSK
-
03
Article about ABL112 published in JITC
2024
-
12
re-certified as Korea Innovative Pharmaceutical Company
-
08
Most Promising Biologics Drug Pipeline (IMAPAC)
-
07
Paid-in capital increase allocated to a third party
-
05
Article about ABL503 published in CCR
2023
-
11
First dosed in phase 1 clinical trial of ABL103 in Korea
-
08
ABL103 Phase 1 clinical trial IND approved by MFDS
-
07
Article about ABL111 published in JITC
-
03
ABL503 Phase 1 clinical trial IND approved by MFDS
2022
-
12
First dosed in Phase 1 clinical trial of ABL301
-
11
Article about ABL301 published in Cell Reports Methods
-
05
Article about ABL501 published in Molecular Therapy
-
03
ABL111 received Orphan-Drug Designation
-
01
Signs licensing agreement with Sanofi
2021
-
12
re-certified as Korea Innovative Pharmaceutical Company
-
08
ABL501 Phase 1 clinical trial IND approved by MFDS
-
07
Review paper on bispecific antibody-based immunotherapy published in Vaccines
-
06
First patient dosed in Phase 1 clinical trial of ABL111
-
04
First patient dosed in Phase 1 clinical trial of ABL503
-
03
ABL111 phase 1 clinical trial IND approved by U.S. FDA
-
02
ABL001 Phase 2 clinical trial IND approved by MFDS
-
01
ABL503 Phase 1 clinical trial IND approved by U.S. FDA
-
01
ABL's 4-1BB bispecific antibody introduced in 'Science Advances'
-
01
ABL001 research published in International Journal of Molecular Sciences
2020
-
10
ABL and LegoChem sign licensing agreement with CStone Pharmaceuticals
-
04
ABL501 designated as National Project
-
04
Signs MOU with Samsung Medical Center for development of cancer immunotherapy
-
03
ABL001 Phase 1b/2a clinical trial approved by MFDS
2019
-
02
Signs licensing agreement with WuXi Biologics
-
11
Signs licensing agreement GenScript Biologics
-
04
Signs licensing agreement with TSD Life Sciences
-
01
Signs MOU with Genome & Company for development of immune checkpoint inhibitors
2018
-
12
ABL Bio IPO on KOSDAQ
-
11
Signs licensing agreement with Compass Therapeutics
-
11
Signs licensing agreement with TRIGR Therapeutics for ABL001
-
09
Signs licensing agreement with Yuhan
-
07
Signs joint development and licensing agreement with I-Mab Biopharma
-
06
Series C Funding (70 billion KRW)
2017
-
08
ABL001 Phase 1 clinical trial IND approved by MFDS
-
03
Series B Funding (20 billion KRW)
2016
-
03
Series A Funding (9 billion KRW)
-
02
Establishment of ABL Bio
